Boston University Launches Center for Brain Recovery

What Is the Boston University Center for Brain Recovery?

Boston University has established the Center for Brain Recovery to bridge laboratory neuroscience with clinical care for patients with neurological injury and neurodegenerative disease. The center brings together researchers across neurology, neuroscience, rehabilitation sciences, biomedical engineering, and speech-language pathology — disciplines that historically operate in silos but increasingly need to collaborate to translate discoveries into therapies.

The launch reflects a broader shift in academic medicine toward translational neuroscience hubs. Conditions like stroke, Alzheimer's, and Parkinson's share overlapping mechanisms — including neuroinflammation, synaptic dysfunction, and impaired neuroplasticity — that may benefit from common therapeutic strategies. By studying recovery and degeneration side by side, the center aims to accelerate the path from molecular insight to bedside treatment.

Why Are Stroke, Alzheimer's, and Parkinson's a Combined Research Priority?

According to the World Health Organization, neurological disorders are now the leading cause of disability globally, with stroke, Alzheimer's disease, and Parkinson's disease among the top contributors. Stroke remains a leading cause of long-term disability in adults, while Alzheimer's affects roughly 7 million Americans and Parkinson's nearly 1 million, with both numbers expected to rise as the population ages.

Despite their different clinical presentations, these conditions share important biological features. Disrupted neuroplasticity — the brain's ability to reorganize and form new connections — is central to recovery after stroke and is impaired in neurodegenerative disease. Neuroinflammation and microglial dysfunction are increasingly recognized drivers in both Alzheimer's and Parkinson's pathology. Research that targets these shared mechanisms may yield therapies with broader applicability than disease-specific approaches.

How Could This Research Translate to Patient Care?

Translational neuroscience centers like this one typically pursue several parallel tracks: identifying novel drug targets, testing emerging therapies in clinical trials, refining rehabilitation protocols, and developing brain-computer interface and neuromodulation devices. Recent advances in the Alzheimer's field — including the FDA-approved anti-amyloid antibodies lecanemab and donanemab — illustrate how decades of basic research can finally yield disease-modifying drugs, though significant work remains to improve efficacy and safety.

For stroke, growing evidence supports intensive, task-specific rehabilitation combined with non-invasive brain stimulation to enhance recovery in the months following injury. In Parkinson's disease, deep brain stimulation, focused ultrasound, and emerging gene therapies are reshaping treatment options. A center that can run preclinical mechanistic studies alongside clinical trials and rehabilitation research is well positioned to move promising findings into practice more rapidly than fragmented programs.